OncoDNA, MyNEO partner on personalized cancer vaccines

By The Science Advisory Board staff writers

April 7, 2021 -- OncoDNA and MyNEO will collaborate on the production of personalized cancer vaccines for patients who have run out of treatment options.

The companies will use their sequencing and bioinformatics technologies to identify and select the most effective neoantigens to target in a patient. OncoDNA will perform whole genome and whole transcriptome sequencing, and MyNEO will handle the advanced interpretation of the sequenced data and design the vaccine construct. Eligible patients would receive tailor-made vaccines and follow-up by monitoring circulating tumor DNA after inoculation using OncoDNA's OncoFollow liquid biopsy platform.

Vaccibody, Nektar begin customized cancer vaccine trial
Vaccibody and Nektar Therapeutics have started a phase I/IIA trial for a personalized cancer DNA vaccine for patients with advanced squamous cell carcinoma...
Elios' customized cancer vaccine shows positive results
Elios Therapeutics' personalized cancer vaccine shows a long-term survival benefit for patients with stage III or IV melanoma, according to final data...
Researchers discuss progress toward personalized cancer vaccines
Highly targeted and adaptable platforms allow researchers to develop cancer vaccines for a multitude of different cancer types and even create personalized...
Personalized cancer vaccines now possible due to discovery of cancer frameshift neoantigens
Researchers from Arizona State University's Biodesign Institute demonstrated experimental proof-of-concept that cancer mutations produce individual neoantigens,...

Copyright © 2021 scienceboard.net

Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter